Biotech and drug stocks
7.53k followers • 31 symbols Watchlist by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies.
Curated by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies. These companies develop speciality drugs and treatments for various diseases and medical conditions. Although there are risks associated with the success of the drug, those that succeed tend to have a strong series of earnings growth over a period of time, especially when they are backed by patents.
The list includes stocks priced at $5 or more with a three-month average daily trading volume in excess of 200,000 shares. This list is generated daily and sorted by market cap; the gains are based on the latest closing price and limited to the top 30 stocks that meet the criteria.
This watchlist is similar to a discontinued watchlist called ‘Battling Cancer’.
Background
Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the global financial markets. We bring these insights to you in the form of watchlists.
Find other winning investment ideas with the Yahoo Finance Screener.
How are these weighted?The stocks in this watchlist are weighted equally.
Performance
| Watchlist | Change today | 1-month return | 1-year return | Total return |
|---|---|---|---|---|
| Biotech and drug stocks | - | - | - | - |
| ^GSPC | +1.11% | -0.43% | +20.31% | +5770.00% |
31 symbols
| Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
|---|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | 804.62 | -16.57 | -2.02% | 4:00 pm GMT-4 | 4.17M | 2.94M | 724.48B |
| NVO | Novo Nordisk A/S | 126.73 | -1.13 | -0.88% | 4:00 pm GMT-4 | 3.04M | 3.93M | 565.11B |
| JNJ | Johnson & Johnson | 160.64 | +1.00 | +0.63% | 4:00 pm GMT-4 | 5.84M | 7.31M | 386.61B |
| ABBV | AbbVie Inc. | 185.16 | +2.99 | +1.64% | 4:00 pm GMT-4 | 6.95M | 5.46M | 326.97B |
| MRK | Merck & Co., Inc. | 125.26 | -0.59 | -0.47% | 4:00 pm GMT-4 | 4.76M | 8.23M | 317.26B |
| RHHBY | Roche Holding AG | 40.76 | -0.01 | -0.02% | 4:00 pm GMT-4 | 494.12k | 2.61M | 260.95B |
| AZN | AstraZeneca PLC | 78.13 | -0.39 | -0.50% | 4:00 pm GMT-4 | 5.83M | 4.10M | 243.05B |
| NVS | Novartis AG | 110.32 | +0.39 | +0.35% | 4:00 pm GMT-4 | 858.85k | 1.37M | 223.35B |
| AMGN | Amgen Inc. | 334.85 | +0.55 | +0.16% | 4:00 pm GMT-4 | 1.51M | 2.45M | 179.63B |
| PFE | Pfizer Inc. | 30.77 | +1.01 | +3.39% | 4:01 pm GMT-4 | 30.49M | 36.71M | 174.36B |
| SNY | Sanofi | 52.4 | -0.70 | -1.32% | 4:00 pm GMT-4 | 1.97M | 2.36M | 131.34B |
| VRTX | Vertex Pharmaceuticals Incorporated | 495.26 | +3.00 | +0.61% | 4:00 pm GMT-4 | 773.77k | 1.18M | 127.80B |
| REGN | Regeneron Pharmaceuticals, Inc. | 1078.63 | +14.44 | +1.36% | 4:00 pm GMT-4 | 375.29k | 437.65k | 118.85B |
| BMY | Bristol-Myers Squibb Company | 50.45 | +5.18 | +11.44% | 4:00 pm GMT-4 | 31.41M | 15.85M | 102.27B |
| GILD | Gilead Sciences, Inc. | 77.01 | +0.50 | +0.65% | 4:00 pm GMT-4 | 7.45M | 7.45M | 95.94B |
| ZTS | Zoetis Inc. | 179.84 | -0.92 | -0.51% | 4:00 pm GMT-4 | 2.44M | 2.44M | 82.06B |
| GSK | GSK plc | 39.86 | +0.79 | +2.02% | 4:00 pm GMT-4 | 2.82M | 3.61M | 81.28B |
| MRNA | Moderna, Inc. | 122.11 | +1.71 | +1.42% | 4:00 pm GMT-4 | 1.88M | 3.94M | 46.80B |
| TAK | Takeda Pharmaceutical Company Limited | 13.77 | +0.10 | +0.73% | 4:00 pm GMT-4 | 2.45M | 1.68M | 43.97B |
| HLN | Haleon plc | 9.23 | +0.09 | +0.98% | 4:00 pm GMT-4 | 6.84M | 5.02M | 42.15B |
| BIIB | Biogen Inc. | 211.17 | -16.27 | -7.15% | 4:00 pm GMT-4 | 2.21M | 1.04M | 30.75B |
| ALNY | Alnylam Pharmaceuticals, Inc. | 234.84 | -3.04 | -1.28% | 4:00 pm GMT-4 | 510.16k | 1.02M | 29.71B |
| ARGX | argenx SE | 494.46 | +8.13 | +1.67% | 4:00 pm GMT-4 | 715.57k | 332.49k | 29.57B |
| BAYRY | Bayer Aktiengesellschaft | 7.46 | -0.01 | -0.13% | 4:00 pm GMT-4 | 31.39k | 1.13M | 29.32B |
| BNTX | BioNTech SE | 85.94 | +1.26 | +1.49% | 4:00 pm GMT-4 | 265.19k | 726.62k | 20.71B |
| ALPMY | Astellas Pharma Inc. | 11 | +0.25 | +2.33% | 3:50 pm GMT-4 | 9.47k | 284.76k | 19.87B |
| TEVA | Teva Pharmaceutical Industries Limited | 17.1 | +0.30 | +1.79% | 4:00 pm GMT-4 | 9.09M | 9.94M | 19.50B |
| GMAB | Genmab A/S | 28.38 | +0.25 | +0.89% | 4:00 pm GMT-4 | 608.30k | 587.57k | 18.01B |
| BGNE | BeiGene, Ltd. | 162.54 | -0.73 | -0.45% | 4:00 pm GMT-4 | 100.27k | 204.98k | 17.37B |
| RPRX | Royalty Pharma plc | 28.79 | +0.11 | +0.38% | 4:00 pm GMT-4 | 1.81M | 2.66M | 17.20B |
- Yahoo Finance Video
Big Tech earnings, jobs report, Fed decision: What to Watch
Big Tech earnings are on deck next week as Microsoft (MSFT), Meta Platforms (META), Apple (AAPL), and Amazon (AMZN) are scheduled to report their second quarter results. Jobs data for July are due out on Friday, August 2, making for a busy week for the US economy as Federal Reserve officials meet for their July FOMC meeting. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Luke Carberry Mogan.
- Yahoo Finance Video
Eli Lilly loses $120B in value over Viking's GLP-1 progress
Pharmaceutical giant Eli Lilly (LLY) lost approximately $120 billion in market value this week following an announcement from competitor Viking Therapeutics (VKTX). The biotech company revealed promising progress toward developing its own weight-loss drug, potentially challenging Eli Lilly's dominance in this market. Yahoo Finance senior health reporter Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Angel Smith
- Yahoo Finance Video
AstraZeneca CEO talks dual supply chain strategy
AstraZeneca (AZN) reported a second-quarter earnings beat, raising its full-year guidance. However, with the upcoming US election potentially impacting operations in regions like China, AstraZeneca CEO Pascal Soriot joins Yahoo Finance reporter Anjalee Khemlani on Catalysts to discuss the company's strategy for navigating these challenges. Soriot outlines AstraZeneca's approach to global expansion, particularly regarding supply chains. He explains that the company is developing two distinct supply chains: one serving Western countries and another "targeted at supplying China and some emerging markets." Importantly, he emphasizes that these two supply chains — the US vs China — will operate "relatively independent from each other." Addressing concerns about the US election's potential impact on operations in China, Soriot notes the company's strategic separation of research and development from manufacturing. This approach allows the company to "source innovation from one part of the world or the other." He acknowledges the diverse policies and rules across different regions, stating that the company adapts its operations accordingly. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Angel Smith
